Key result
Pharmacologic therapy in patients with coexisting chronic heart failure and chronic kidney disease is complicated by their complex interplay and underrepresentation in clinical trials.
This review highlights the complex interplay between renal dysfunction and pharmacologic therapy in patients with coexisting chronic heart failure and chronic kidney disease, a population often underrepresented in trials.
CKD in HF raises adverse risks and treatment complexity; leaves open dedicated trials to guide therapy in this underrepresented group.
Chronic kidney disease is common in patients with chronic heart failure and has important clinical implications. The coexistence of these two syndromes is associated with a higher risk of adverse outcome and increases the difficulties of heart failure treatment because of the complex interplay between renal dysfunction and pharmacologic therapy. The underrepresentation of patients with chronic kidney disease in most heart failure trials contributes to the suboptimal treatment of this high-risk population in clinical practice. In the present review, we briefly examine the pathophysiologic mechanisms connecting chronic kidney disease and chronic heart failure and discuss the therapeutic approach to patients affected by both conditions.
No takes yet. Share an insight, caveat, or question.
Acquarone et al. (2009) conducted a review in Chronic heart failure and chronic kidney disease. Pharmacologic therapy was evaluated. Pharmacologic therapy in patients with coexisting chronic heart failure and chronic kidney disease is complicated by their complex interplay and underrepresentation in clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: